GlobalGov › United States › Award

OREXO US INC won CLINICAL DEVELOPMENT OF OX390 (ATIPAMEZOLE) AS AN ?2 AGONIST REVERSAL AGENT FOR HUMAN USE TO COUNTERACT THE SEDATIVE EFFECTS OF XYLAZINE, from Office of Assistant Secretary for Preparedness and Response

Office of Assistant Secretary for Preparedness and Response · United States government award

GlobalGov surfaces government contract awards from around the world, including the markets your competitors overlook.

$8.5M
Award Value
September 24, 2025
Award Date
Awarded
Status

Award Overview

OREXO US INC was awarded CLINICAL DEVELOPMENT OF OX390 (ATIPAMEZOLE) AS AN ?2 AGONIST REVERSAL AGENT FOR HUMAN USE TO COUNTERACT THE SEDATIVE EFFECTS OF XYLAZINE, by Office of Assistant Secretary for Preparedness and Response in United States, tracked by GlobalGov. The award is valued at $8.5M. It was awarded on September 24, 2025. Classification: NAICS 541714, PSC AN13. Full award details and the issuing agency are below.

See who is winning government contracts in this market — and the open opportunities coming next. Track awards, incumbents, and recompetes worldwide. Free for 14 days, no card.

Start Free

Award Details

AwardeeOREXO US INC
Awarding agencyOffice of Assistant Secretary for Preparedness and Response
CountryUnited States
Award value$8.5M
Award dateSeptember 24, 2025
NAICS541714
PSCAN13
Place of performanceUnited States
Last verifiedSeptember 2, 2026

Source: U.S. Government (USAspending.gov) — public domain. GlobalGov is not affiliated with or endorsed by the United States Government.

United States market overview →Browse open opportunities →

Track every United States contract award and the opportunities behind them. Free for 14 days.

Get incumbent intelligence, recompete alerts, and deadline tracking for this market and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required